Introduction {#s1}
============

Breast cancer is the most common type of female malignancy all over the world. Coffee, one of most known risk factors, may be crucial in the etiology of breast cancer [@pone.0052681-Parkin1]. The association between coffee intake and breast cancer risk is biologically plausible because of its complex make-up of chemicals, e.g., caffeine and polyphenolic compounds such as flavonoids and lignans [@pone.0052681-Scalbert1]--[@pone.0052681-Welsch1]. Coffee can play a dual role as both a carcinogen, in which it enhances cell proliferation, and a chemo-preventive agent with anti-oxidative and weakly estrogenic properties [@pone.0052681-Olsen1], [@pone.0052681-Lee1]. A number of previous epidemiologic studies have estimated the association between coffee consumption and breast cancer risk. However, the results were inconsistent. An earlier meta-analysis relating the consumption of coffee to cancer of various sites by Arab [@pone.0052681-Arab1] reported a null association with breast cancer risk. But another meta-analysis published in 2009 suggested that high coffee consumption was associated with a borderline reduction of breast cancer risk [@pone.0052681-Tang1]. Since the meta-analysis, several large prospective cohort studies have estimated the association between coffee consumption and breast cancer risk [@pone.0052681-Li1]--[@pone.0052681-Fagherazzi1]. Therefore, to provide an updated results on this topic, we systematically conducted a meta-analysis by combining all available data of both case--control and cohort studies.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

We searched the databases MEDLINE and EMBASE to identify relevant studies published in English through July 2012. The following keywords were used in searching: "caffeine", "coffee", or "dietary factors", combined with "breast cancer", "breast carcinoma," or "breast neoplasm". We also reviewed references cited in the selected articles. The eligible studies had to meet the following criteria: (i) They had a case--control or cohort study design; (ii) The outcome of interest was primary breast cancer; (iii) The exposure of interest was coffee consumption. (iv) Relative risk (RR) and their 95% confidence intervals (CIs) could be extracted or calculated from relevant articles.

Data extraction {#s2b}
---------------

The following information was extracted from each included study: first author\'s last name, study design, country of origin, study period, number of cases and subjects, adjustment for potential confounders, the exposure to coffee consumption, RR and corresponding 95% CIs for every category of coffee intake. For each study, low coffee consumption was defined as the reference category, high coffee consumption as the greatest degree of control, and moderate coffee consumption fell in between. All the data were extracted independently by two authors (Li XJ and Ren ZJ), and the disagreement was solved by discussion.

Statistical analysis {#s2c}
--------------------

Study-specific RRs/odds ratios (ORs) and 95% CIs for low to moderate consumption and high consumption level were extracted from each study, and then we pooled the overall RR/OR using the inverse of the corresponding variances as weights. Because breast cancer is rare, ORs in case--control studies yield similar estimates of RR [@pone.0052681-Bradburn1]. Heterogeneity of effect size across studies was tested by I^2^ statistics (I^2^\>50% is considered significant). We calculated summary estimates of the RR using random-effects models, which consider both within- and between-study variation. Sensitivity analyses were also conducted, in which one study at a time was removed to analyze the influence of a single study on the pooled RR.

To obtain the information on a dose--response relationship, we considered the increment of 2 cup per day [@pone.0052681-Orsini1], [@pone.0052681-Greenland1]. For each study, we calculated the median cups of coffee consumption for each category by assigning the midpoint of upper and lower boundaries in each category as the average consumption. If the upper bound was not provided, we assumed that it had the same amplitude as the preceding category. Because this method requires the risk estimates with their variances for at least 3 quantitative exposure categories, we excluded studies showing two categories of exposure only [@pone.0052681-Hunter1]--[@pone.0052681-Mannisto1]. And the summary RR for breast cancer risk with 2 cups/day increment of coffee consumption was obtained by pooling the corresponding study-specific RRs with random-effects models.

Studies were not eligible if the required data were not reported or could not be estimated. If coffee consumption was indicated by milliliter, we defined 125 ml of coffee equal to 1 cup.

The subgroup analyses according to geographic region, ER status, and menopausal status were performed to assess the potential effect of these variables on outcomes. The funnel plots with Begg\'s rank correlation and Egger regression tests were performed to detect publication bias [@pone.0052681-Egger1]. All statistical analyses were performed with STATA (version 12.0; Stata Corp).

Results {#s3}
=======

Literature search {#s3a}
-----------------

We initially identified 186 potentially eligible studies. Most were excluded because the exposure or endpoint was not relevant to our analysis. After assessing the full-text of the 36 potentially relevant articles, we identified 26 eligible studies [@pone.0052681-Li1]--[@pone.0052681-Fagherazzi1], [@pone.0052681-Hunter1]--[@pone.0052681-Mannisto1], [@pone.0052681-Vatten1]--[@pone.0052681-Baker1]. The main reasons for exclusion were as follows: 5 studies [@pone.0052681-Le1]--[@pone.0052681-Stensvold1] did not provide a 95% CI. We tried to contact with authors for original data, but we got no reply. Because of relative small sample and poor study design, these original data was not necessary for meta-analysis; 2 studies [@pone.0052681-Rosenblatt1], [@pone.0052681-Johnson1] were conducted among male subjects. We further excluded the other 3 studies, because they evaluated the association in BRCA1 or BRCA2 mutation carriers [@pone.0052681-Gronwald1]--[@pone.0052681-Kotsopoulos1]. Finally, 16 cohort studies [@pone.0052681-Boggs1]--[@pone.0052681-Fagherazzi1], [@pone.0052681-Hunter1], [@pone.0052681-Vatten1]--[@pone.0052681-Ganmaa1] and 10 case-control studies [@pone.0052681-Li1], [@pone.0052681-McLaughlin1], [@pone.0052681-Mannisto1], [@pone.0052681-Rosenberg1]--[@pone.0052681-Baker1] were included in the meta-analysis. A flow chart showing the study selection process is presented in [Figure 1](#pone-0052681-g001){ref-type="fig"}.

![Flow chart of the selection of publications included in the meta-analysis.](pone.0052681.g001){#pone-0052681-g001}

Study characteristics {#s3b}
---------------------

We identified 26 studies including 49497 incident cases of breast cancer and 863067 participants that were eligible for meta-analysis [@pone.0052681-Li1]--[@pone.0052681-Fagherazzi1], [@pone.0052681-Hunter1]--[@pone.0052681-Mannisto1], [@pone.0052681-Vatten1]--[@pone.0052681-Baker1]. The characteristics of the included studies are summarized in [Table S1](#pone.0052681.s002){ref-type="supplementary-material"}. By study design, 10 case--control studies [@pone.0052681-Li1], [@pone.0052681-McLaughlin1], [@pone.0052681-Mannisto1], [@pone.0052681-Rosenberg1]--[@pone.0052681-Baker1] and 16 prospective cohort studies [@pone.0052681-Boggs1]--[@pone.0052681-Fagherazzi1], [@pone.0052681-Hunter1], [@pone.0052681-Vatten1]--[@pone.0052681-Ganmaa1]. By geographic region, 12 studies were conducted in Europe [@pone.0052681-Li1], [@pone.0052681-Larsson1], [@pone.0052681-Pathy1], [@pone.0052681-Fagherazzi1], [@pone.0052681-Mannisto1], [@pone.0052681-Vatten1], [@pone.0052681-Hoyer1], [@pone.0052681-Michels1], [@pone.0052681-Hirvonen1], [@pone.0052681-LaVecchia1]--[@pone.0052681-Tavani1], 11 in the United States [@pone.0052681-Boggs1], [@pone.0052681-Ishitani1], [@pone.0052681-Gierach1], [@pone.0052681-Nilsson1], [@pone.0052681-Hunter1], [@pone.0052681-McLaughlin1], [@pone.0052681-Folsom1], [@pone.0052681-Ganmaa1], [@pone.0052681-Rosenberg1], [@pone.0052681-Wu1], [@pone.0052681-Baker1] and 3 in Asia [@pone.0052681-Key1], [@pone.0052681-Suzuki1], [@pone.0052681-Lubin1]. One study [@pone.0052681-Vatten1] only adjusted for age, whereas the other 25 studies adjusted for a wide range of potential confounders for breast cancer, including age, BMI, family history of breast cancer, smoking, alcohol, geographic area, parity, age at first birth, age at menarche and menopause, oral contraceptive and other female hormone use.

High and low to moderate coffee consumption {#s3c}
-------------------------------------------

The multivariable-adjusted RRs in each study and the pooled RR of breast cancer for the highest versus lowest categories of coffee intake are presented in [Figure 2](#pone-0052681-g002){ref-type="fig"} and [Table 1](#pone-0052681-t001){ref-type="table"}. The pooled RR of breast cancer for the highest versus lowest categories of coffee intake was 0.96 (95% CI 0.93--1.00). Stratifying by study design, the pooled RRs for case--control studies and cohort studies were 0.93 (95% CI 0.86--1.00) and 0.98 (95% CI 0.93--1.02), respectively. Stratifying by geographic region, the summary RRs were 0.96 (95% CI 0.90--1.02) for studies performed in Europe, 0.97 (95% CI 0.92--1.01) for studies performed in the United States, and 0.92 (95% CI 0.64--1.33) for studies performed in Asia. Stratifying by estrogen receptor(ER) status, the pooled RRs for ER-negative studies and ER-positive studies were 0.81 (95% CI 0.67--0.97) and 1.01 (95% CI 0.93--1.09), respectively. According to menopausal status, the pooled RR for premenopausal cancers was 1.00 (95% CI 0.72--1.40), and the pooled RR for postmenopausal cancers was 0.92 (95% CI 0.79--1.09). [Figure 3](#pone-0052681-g003){ref-type="fig"} and [Table 1](#pone-0052681-t001){ref-type="table"} present the estimated RRs for low to moderate versus lowest coffee consumption, according to selected covariates. The summary RR was 0.99 (95% CI 0.95--1.04) for low to moderate versus lowest coffee consumption. In the subgroup analysis by study design, no increased risk was found for either cohort studies (OR = 0.98, 95% CI = 0.95--1.01) or case--control studies (OR = 0.98, 95% CI = 0.90--1.13). Stratified analyses were also performed according to geographic region. The RR was 1.00 (95% CI, 0.92--1.08) when considering 11 studies conducted in Europe, 0.78 (95% CI, 0.49--1.24) for 9 studies from United States and 1.00 (95% CI, 0.95--1.04) for 3 Asian studies. In addition, No significant differences by Menopause status were found.

![Forest plot of case--control and cohort studies of the risk of breast cancer for the highest versus lowest coffee drinking categories.\
The combined Relatives risks (RRs) and 95% confidence intervals (CIs) were calculated using the random-effects model.](pone.0052681.g002){#pone-0052681-g002}

![Forest plot of case--control and cohort studies of the risk of breast cancer for the low-to-moderate versus the lowest coffee drinking categories.\
The combined Relatives risks (RRs) and 95% confidence intervals (CIs) were calculated using the random-effects model.](pone.0052681.g003){#pone-0052681-g003}

10.1371/journal.pone.0052681.t001

###### Main results of meta-analysis.

![](pone.0052681.t001){#pone-0052681-t001-1}

  Group                           No. of studies   Relative risk (95%CI)   Heterogeneity  
  ------------------------------ ---------------- ----------------------- --------------- -------
  Highest vs. lowest                                                                      
  All studies                           26           0.96 (0.93--1.00)         0.0%        0.769
  Study design                                                                            
  All cohort studies                    16           0.98 (0.93--1.02)         0.0%        0.736
  All case-control studies              10           0.93 (0.86--1.00)         0.0%        0.644
  Geographic area                                                                         
  Europe                                12           0.96 (0.90--1.02)         0.0%        0.780
  United States                         11           0.97 (0.92--1.01)         0.0%        0.703
  Asia                                  3            0.92 (0.64--1.33)         58.1%       0.092
  Estrogen receptor(ER) status                                                            
  ER-negative                           5            0.81 (0.67--0.97)         26.1%       0.211
  ER-positive                           5            1.01 (0.93--1.09)         0.0%        0.909
  Menopause status                                                                        
  Premenopause                          5            1.00 (0.72--1.40)         58.3%       0.048
  Postmenopause                         5            0.92 (0.79--1.09)         20.4%       0.285
  Low-to-moderate vs. lowest                                                              
  All studies                           23           0.99 (0.95--1.04)         67.8%       0.000
  Study design                                                                            
  All cohort studies                    15           0.98 (0.95--1.01)         22.7%       0.201
  All case-control studies              8            1.01 (0.90--1.13)         83.3%       0.000
  Geographic area                                                                         
  Europe                                11           1.00 (0.92--1.08)         74.8%       0.000
  United States                         9            1.00 (0.95--1.04)         47.3%       0.056
  Asia                                  3            0.98 (0.69--1.41)         82.7%       0.003
  Menopause status                                                                        
  Premenopause                          2            0.94 (0.83--1.07)         0.0%        0.638
  Postmenopause                         2            0.99 (0.90--1.09)         0.0%        0.910
  Increment of 2 cups/d                                                                   
  All studies                           23           0.98 (0.97--1.00)         0.0%        0.795
  Study design                                                                            
  All cohort studies                    15           0.98 (0.97--1.00)         0.0%        0.554
  All case-control studies              8            0.98 (0.96--1.00)         0.0%        0.802
  Geographic area                                                                         
  Europe                                11           0.98 (0.97--1.00)         0.0%        0.920
  United States                         9            0.98 (0.96--1.01)         1.6%        0.421
  Asia                                  3            0.98 (0.69--1.41)         49.1%       0.140
  Menopause status                                                                        
  Premenopause                          2            0.91 (0.81--1.03)         44.7%       0.179
  Postmenopause                         2            0.93 (0.77--1.13)         86.0%       0.008

Dose--response meta-analysis {#s3d}
----------------------------

23 studies were included for the dose--response analysis of coffee intake and risk of breast cancer [@pone.0052681-Li1]--[@pone.0052681-Fagherazzi1], [@pone.0052681-Vatten1]--[@pone.0052681-Baker1]. The pooled RR for a 2 cups per day increment in coffee intake was 0.98 (95%CI 0.97--1.00) ([Figure 4](#pone-0052681-g004){ref-type="fig"}), similarly for cohort studies (pooled RR = 0.98, 95% CI = 0.97--1.00) and case--control studies (pooled RR = 0.98, 95% CI = 0.96--1.00) ([Table 1](#pone-0052681-t001){ref-type="table"}). The summary RRs were 0.98 (95% CI 0.97--1.00) for studies conducted in Europe, 0.98 (95% CI 0.96--1.01) for studies conducted in the United States, and 0.98 (95% CI, 0.69--1.41) ([Table 1](#pone-0052681-t001){ref-type="table"}) for studies conducted in Asia. When grouped by menopausal status, the pooled RR for premenopausal cancers was 0.91 (95% CI 0.81--1.03), and the pooled RR for postmenopausal cancers was 0.93 (95% CI 0.77--1.13) ([Table 1](#pone-0052681-t001){ref-type="table"}).

![Forest plot of case--control and cohort studies of the risk of breast cancer for the increment of two cups of coffee per day.\
The combined Relatives risks (RRs) and 95% confidence intervals (CIs) were calculated using the random-effects model.](pone.0052681.g004){#pone-0052681-g004}

Publication bias {#s3e}
----------------

There was no indication of publication bias from either visualization of the funnel plot, Begg\'s test (p = 0.84), or Egger\'s test (p = 0.54). The sensitivity analysis confirmed the stability of our results.

Discussion {#s4}
==========

This meta-analysis showed a borderline significant association between coffee consumption and decreased risk of breast cancer. The results of our meta-analysis were consistent with those in the earlier meta-analysis which contained 25250 cases [@pone.0052681-Tang1]. Moreover, in the subgroup analysis by estrogen receptor(ER) status, we observed a significant inverse association between high coffee consumption and breast cancer risk. There was, however, relevant heterogeneity across studies, particularly according to study population and menopausal status. The relatively small sample size in Asia and the difference in the definition of menopausal status might contribute to the result.

The mechanisms by which coffee may affect breast carcinogenesis are complex and remain unclear. Coffee can both stimulate and suppress the development of mammary tumors in vitro [@pone.0052681-VanderPloeg1], [@pone.0052681-Wolfrom1]. Coffee might contain compounds that differentially affect breast cancer of different ER subtypes. For example, coffee has been shown to significantly contribute to levels of plasma enterolactone [@pone.0052681-Horner1], a phytoestrogen reported to be associated with a significant decrease in ER-negative breast cancer risk [@pone.0052681-Olsen2]. The presence of such compounds that specifically attenuates the risk of ER-negative breast cancer may contribute to our result in ER-negative subgroup analysis.

There were 5 studies [@pone.0052681-Li1], [@pone.0052681-Boggs1], [@pone.0052681-Larsson1], [@pone.0052681-Gierach1], [@pone.0052681-Fagherazzi1] in our subgroup analysis by ER status, but a population-based case-control study reported by Li et al [@pone.0052681-Li1], accounted for our result of an inverse association between coffee intake and the risk of ER-negative breast cancer. In this multivariate-adjusted Swedish study, the pooled RR of ER-negative breast cancer for postmenopausal women who drank more than five cups of coffee per day was 0.43 (95% CI 0.25--0.72). However, in a large cohort study reported by Ishitani et al [@pone.0052681-Ishitani1], there was a significant positive association between caffeine consumption and risk of developing estrogen receptor-negative and progesterone receptor-negative (ER−PR−) breast cancer according to hormone receptor status. Another cohort study [@pone.0052681-Hirvonen1], found no significant association between caffeine consumption and breast cancer risk according to hormone receptor status. Bageman et al [@pone.0052681-Bageman1], investigated the potential effect of CYP1A2 genotype on the relationship between coffee consumption and breast cancer risk among ER-negative patients. Although the CYP1A2 genotype alone did not affect breast cancer risk, the authors noted that, coffee consumption (≥2 cups per day) combined with the *CYP1A2\*1F* A/A genotype is associated with a greater proportion of ER− tumors among patients with breast cancer in a population-based study (OR = 4.2; 95% CI, 1.9--9.3; *P* = 0.0002). Although the results appear inconsistent, it could be because of the different coffee-related variables measured. For instance, caffeine is only one out of the many different compounds contained in coffee, and thus caffeine intake is perhaps not a valid substitute for measuring the total effects of coffee consumption. In addition, the discrepancy might be attributed to other factors related to coffee drinking, such as brewing method, bean type, and caffeine content. Concerning relative small sample size, we cannot exclude the possibility that our findings in some subgroups may be a result of chance. More studies are needed to refute or confirm the associations that we observed in some subgroups.

The current meta-analysis had some advantages. First, the number of total cases included in the meta-analysis was substantial (n = 49497 cases). The pooled RRs of breast cancer for coffee intake were consistent with those in the previous meta-analysis which contained 25250 cases [@pone.0052681-Tang1]. Second, we observed an inverse association between coffee intake and risk of ER-negative breast cancer. Breast cancer is characterized by genetic heterogeneity, encompassing different tumor types with distinct biologic features and clinical behaviors. So it indicated that researchers need to detail the clinical pathological parameters in future studies. Third, we found little evidence of publication bias in this meta-analysis.

Despite these advantages, some limitations of our meta-analysis should be acknowledged. First, misclassification of coffee intake and thus misclassified coffee components are inevitable due to self-reported intake. Second, a meta-analysis is unable to solve problems with confounding factors that could be inherent in the included studies. Third, although many of studies had adjusted for important risk factors for breast cancer, unmeasured variables may also have influenced results of individual studies. Fourth, not all studies were included for the dose--response analysis due to lack of data. Fifth, studies included in this meta-analysis were mostly conducted in Europe, the United States, and Asia. Therefore, additional research in other populations is warranted to generalize the findings. Sixth, potential publication bias might influence the findings, yet little evidence of publication bias was observed. Finally, the results of meta-analysis in some subgroups (e.g. estrogen receptor status and Menopause status) need further to be investigated, because of limited data.

In conclusion, our meta-analysis suggests that coffee consumption is not related to overall risk of breast cancer. However, our data suggest that high coffee consumption may decrease risk of ER--negative breast cancer, but these findings may be due to chance and warrant further study.
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